A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)

Allergan

Status: Completed

Conditions: Macular Edema

Treatments: Drug: dexamethasone intravitreal implant 0.7 mg

Study type: Observational

Funder types: Industry

Identifiers

NCT01445626

MAF/AGN/OPH/RET/010

Details and patient eligibility

About

This study will use retrospective data to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular oedema due to Retinal Vein Occlusion (RVO).

Enrollment: 87 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Macular oedema in the study eye due to BRVO or CRVO
• Received at least 2 OZURDEX® injections in the study eye

Exclusion criteria

• Received OZURDEX® injections as part of or during any clinical study

Trial design

87 participants in 1 patient group

All participants

Description:

Patients who received at least two OZURDEX® (dexamethasone intravitreal implant) injections.

Treatment:

Drug: dexamethasone intravitreal implant 0.7 mg